ImmunoGen starts Phase I/II study

IMGN partner SmithKline (SBH; LSE:SB) began U.S. Phase I/II safety testing of huC242- DM1/SB-408075, a humanized monoclonal antibody combined with the maytansinoid toxin DM1 to treat refractory colore...